The phenotype of Down syndrome, trisomy of chromosome 21, is hypothesized to be produced by the increased expression due to gene dosage of normal chromosome 21 genes. Chromosome 21 encodes a number of proteins that, based on experimental evidence or domain composition, are classed as transcription factors or their co-regulators. Other chromosome 21 proteins contribute to post-translational modification of transcription factors, including their phosphorylation, dephosphorylation and sumoylation. Several of these chromosome 21 proteins and the pathways in which they function have overlapping transcription factor specificities. Thus, altered stoichiometry in complexes and altered levels of activation of individual transcription factors may contribute to the Down syndrome phenotype by perturbation of downstream gene expression. Here we review recent data on four chromosome 21 proteins: NRIP1, GABPA, DYRK1A and SUMO3. We discuss the implications for activation of ELK, CREB, C/EBP \(\alpha,\beta\), estrogen and glucocorticoid receptors, and for expression of BDNF. Each of these proteins is relevant to learning, behavior and/or development and therefore perturbation of their activation may contribute to the Down syndrome phenotype.
Similar content being viewed by others
References
Ahi J., Radulovic J. and Spiess J. (2004). The role of hippocampal signaling cascades in consolidation of fear memory. Behav. Brain Res. 149:17–31
Akeson E. C., Lambert J. P., Narayanswami S., Gardiner K., Bechtel L. J. and Davisson M. T. (2001). Ts65Dn – localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet. Cell Genet. 93:270–276
Amano K., Sago H., Uchikawa C., Suzuki T., Kotliarova S. E., Nukina N., Epstein C. J. and Yamakawa K. (2004). Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum. Mol. Genet. 13:1333–40
Ayberk K. M., Ilker K. M., Dierssen M. and Ceri D. D. (2004). Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 1022:101-109
Bambrick L. L., Yarowsky P. J. and Krueger B. K. (2003). Altered astrocyte calcium homeostasis and proliferation in theTs65Dn mouse, a model of Down syndrome. J. Neurosci. Res. 73:89–94
Begay V., Smink J. and Leutz A. (2004). Essential requirement of CCAAT/enhancer binding proteins in embryogenesis. Mol Cell Biol. 24:9744–51
Bimonte-Nelson H. A., Hunter C. L., Nelson M. E. and Granholm A. C. (2003). Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 139:47–57
Bohren K. M., Nadkarni V., Song J. H., Gabbay K. H. and Owerbach D. (2004) A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279:27233–27238
Branchi I., Bichler Z., Minghetti L., Delabar J. M., Malchiodi-Albedi F., Gonzalez M. C., Chettouh Z., Nicolini A., Chabert C., Smith D. J., Rubin E. M., Migliore-Samour D. and Alleva E. (2004). Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J Neuropathol Exp Neurol. 63:429–440
Brinton R. D. (2001). Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer’s disease: recent insights and remaining challenges. Learn Mem. 8:121–133
Brinton R. D. (2004). Impact of estrogen therapy on Alzheimer’s disease: a fork in the road?. CNS Drugs 18:405–422
Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H. and Yankner B. A. (2002). Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down’s syndrome. Neuron 33:677–688
Castet A., Boulahtouf A., Versini G., Bonnet S., Augereau P., Vignon F., Khochbin S., Jalaguier S. and Cavailles V. (2004). Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition. Nucleic Acids Res. 32:1957–1966
Cataldo A. M., Petanceska S., Peterhoff C. M., Terio N. B., Epstein C. J., Villar A., Carlson E. J., Staufenbiel M. and Nixon R. A. (2003). App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci. 23:6788–6792
Cavailles V., Dauvois S., L’Horset F., Lopez G., Hoare S., Kushner P. J. and Parker M. G. (1995). Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 14:3741–3751
Chan R. Y., Boudreau-Lariviere C., Angus L. M., Mankal F. A. and Jasmin B. J. (1999). An intronic enhancer containing an N-box motif is required for synapse- and tissue-specific expression of the acetylcholinesterase gene in skeletal muscle fibers. Proc. Natl. Acad. Sci. USA 96:4627–4632
Chang K. T., Shi Y. J. and Min K. T. (2003). The Drosophila homolog of Down’s syndrome critical region 1 gene regulates learning: implications for mental retardation. Proc. Natl. Acad. Sci. USA 100:15794–15799
Cooper J. D., Salehi A., Delcroix J. D., Howe C. L., Belichenko P. V., Chua-Couzens J., Kilbridge J. F., Carlson E. J., Epstein C. J. and Mobley W. C. (2001) Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. USA 98:10439–10444
Crnic L. S., Pennington B. F. (2000) Down syndrome: neuropsychology and animal models. Progr. Infancy Res. 1: 69–111
Davisson M. T., Costa A. C. S. (1999) Mouse models of Down syndrome. In: Popko B. (eds) Mouse models in the study of genetic neurological disorders. Advances in neurochemistry. Plenum Press, New York, pp. 297–327
Dhandapani K. M., Brann D. W. (2002) Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol. Reprod. 67: 1379–1385
Dauphinot L., Lyle R., Rivals I., Dang M. T., Moldrich R. X., Golfier G., Ettwiller L., Toyama K., Rossier J., Personnaz L., Antonarakis S. E., Epstein C. J., Sinet P. M., Potier M. C. (2005) The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum. Mol. Genet. 14: 373–384
Eaton E. M., Sealy L. (2003) Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3. J. Biol. Chem. 278: 33416–33421
Engidawork E., Lubec G. (2003) Molecular changes in fetal Down syndrome brain. J. Neurochem. 84: 895–904
Epstein C. J. (1981) The consequences of chromosome imbalance: principles, mechanisms, models. Cambridge University Press, New York
Ermak G., Harris C. D., Davies K. J. (2002) The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress. FASEB J. 16: 814–824
Fromm L., Burden S. J. (2001) Neuregulin-1-stimulated phosphorylation of GABP in skeletal muscle cells. Biochemistry. 40: 5306–5312
Galceran J., de Graaf K., Tejedor F. J., Becker W. (2003) The MNB/DYRK1A protein kinase: genetic and biochemical properties. J. Neural Transm. Suppl. 67: 139–148
Gardiner K., Fortna A., Bechtel L., Davisson M. T. (2003) Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318: 137–147
Gardiner K. (2004) Gene-dosage effects in Down syndrome and trisomic mouse models. Genome Biol. 5: 244–247
Gardiner K., Davisson M. T., Crnic L. S. (2004) Building protein interaction maps for Down’s syndrome. Brief Funct. Genom. Proteom. 3: 142–156
Gill G. (2003) Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 13: 108–113
Gocke C. B., Yu H., Kang J. (2005) Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J. Biol. Chem. 280: 5004–5012
Granholm A. C., Ford K. A., Hyde L. A., Bimonte H. A., Hunter C. L., Nelson M., Albeck D., Sanders L. A., Mufson E. J., Crnic L. S. (2002) Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol. Behav. 77: 371–385
Groth R. D., Mermelstein P. G. (2003) Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J. Neurosci. 23: 8125–8134
Groth R. D., Dunbar R. L., Mermelstein P. G. (2003) Calcineurin regulation of neuronal plasticity. Biochem. Biophys. Res. Commun. 311: 1159–1171
Helguera P., Pelsman A., Pigino G., Wolvetang E., Head E., Busciglio J. (2005) ets-2 promotes the activation of a mitochondrial death pathway in Down’s syndrome neurons. J. Neurosci. 25: 2295–2303
Holmstrom S., Van Antwerp M. E., Iniguez-Lluhi J. A. (2003) Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy. Proc. Natl. Acad. Sci. USA 100: 15758–15763
Holtzman D. M., Santucci D., Kilbridge J., Chua-Couzens J., Fontana D. J., Daniels S. E., Johnson R. M., Chen K., Sun Y., Carlson E., Alleva E., Epstein C. J., Mobley W. C. (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. USA 93: 13333–8
Hyde L. A., Frisone D. F., Crnic L. S. (2001) Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav. Brain Res. 118: 53–60
Hyde L. A., Crnic L. S. (2001) Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer’s disease. Behav. Neurosci. 115: 1239–1246
Insausti A. M., Megias M., Crespo D., Cruz-Orive L. M., Dierssen M., Vallina I. F., Insausti R., Florez J. (1998) Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci. Lett. 253: 175–178
Kahlem P., Sultan M., Herwig R., Steinfath M., Balzereit D., Eppens B., Saran N. G., Pletcher M. T., South S. T., Stetten G., Lehrach H., Reeves R. H., Yaspo M. L. (2004) Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 14: 1258–1267
Kellendonk C., Gass P., Kretz O., Schutz G., Tronche F. (2002) Corticosteroid receptors in the brain: gene targeting studies. Brain Res. Bull. 57: 73–83
Kleschevnikov A. M., Belichenko P. V., Villar A. J., Epstein C. J., Malenka R. C., Mobley W. C. (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24: 8153–8160
Korenberg J. R., Chen X.-N., Schipper R., Sun Z., Gonsky R., Gerwehr S., Carpenter N., Daumer C., Dignan P., Disteche C. et al. (1994) Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. USA 91: 4997–5001
Kotaja N., Karvonen U., Janne O. A., Palvimo J. J. (2002) The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 277: 30283–30288
Kramer D., Fresu L., Ashby D. S., Freeman T. C., Genazzani A. A. (2003) Calcineurin controls the expression of numerous genes in cerebellar granule cells. Mol Cell Neurosci. 23: 325–330
Lapenta V., Chiurazzi P., van der Spek P., Pizzuti A., Hanaoka F., Brahe C. (1997) SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family Genomics 40: 362–366
Lee J. I., Ahnn J. (2004) Calcineurin in animal behavior. Mol. Cells 17: 390–396
Li Y., Wang H., Wang S., Quon D., Liu Y. W., Cordell B. (2003) Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. USA 100: 259–264
Lonze B. E., Ginty D. D. (2002) Function and regulation of CREB family transcription factors in the nervous system20. Neuron 35: 605–623
Lott I. T., Head E. (2001) Down syndrome and Alzheimer’s disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 7: 172–178
Lund P. K., Hoyt E. C., Bizon J., Smith D. R., Haberman R., Helm K., Gallagher M. (2004) Transcriptional mechanisms of hippocampal aging. Exp. Gerontol. 39: 1613–1622
Lyle R., Gehrig C., Neergaard-Henrichsen C., Deutsch S., Antonarakis S. E. (2004) Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res. 14: 1268–1274
Mansuy I. M. (2003) Calcineurin in memory and bidirectional plasticity. Biochem. Biophys. Res. Commun. 311: 1195–1208
Mao J., Maye P., Kogerman P., Tejedor F. J., Toftgard R., Xie W., Wu G., Wu D. (2002) Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1. J. Biol. Chem. 277: 35156–35161
Mao R., Zielke C. L., Zielke H. R., Pevsner J. (2003) Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 81: 457–467
McEwen B. (2002) Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57: 357–384
Michels F., Stam J. C., Hordijk P. L., van der Kammen R. A., Ruuls-Van Stalle L., Feltkamp C. A., Collard J. G. (1997) Regulated membrane localization of Tiam1, mediated by the NH2-terminal Pleckstrin homology domain, is required for Rac-dependent membrane ruffling and c-Jun NH2-terminal kinase activation. J. Cell Biol. 137: 387–398
Mohney, R. P., Das, M., Bivona, T. G., Hanes, R., Adams, A. G., Philips, M. R., and O’Bryan, J. P. (2003). Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J. Biol. Chem. 278: 47038–47045
Morris A. F., Vaughan S. E., Vaccaro P. (1982) Measurements of neuromuscular tone and strength in Down’s syndrome children. J. Ment. Defic. Res. 26: 41–46
Motonaga K., Itoh M., Hirayama A., Hirano S., Becker L. E., Goto Y., Takashima S. (2001) Up-regulation of E2F-1 in Down’s syndrome brain exhibiting neuropathological features of Alzheimer-type dementia. Brain Res. 905: 250–253
Muller M., Holsboer F., Keck M. E. (2002) Genetic modification of corticosteroid receptor signalling: novel insights into pathophysiology and treatment strategies of human affective disorders. Neuropeptides 36: 117–1131
O’Leary D. A., Pritchard M. A., Xu D., Kola I., Hertzog P. J., Ristevski S. (2004) Tissue-specific overexpression of the HSA21 gene GABPalpha: implications for DS. Biochim. Biophys. Acta 1739: 81–87
Olson L. E., Richtsmeier J. T., Leszl J., Reeves R. H. (2004a) A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306: 687–690
Olson L. E., Roper R. J., Baxter L. L., Carlson E. J., Epstein C. J., Reeves R. H. (2004b) Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 230: 581–589
Oitzl M. S., Reichardt H. M., Joels M., de Kloet E. R. (2001) Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. Proc. Natl. Acad. Sci. USA 98: 12790–12795
Parker A. W., Bronks R., Snyder C. W. Jr. (1986) Walking patterns in Down’s syndrome. J. Ment. Defic. Res. 30: 317–330
Pennington B. F., Moon J., Edgin J., Stedron J., Nadel L. (2003) The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 74: 75–93
Robert I., Sutter A., Quirin-Stricker C. (2002) Synergistic activation of the human choline acetyltransferase gene by c-Myb and C/EBPbeta. Brain Res. Mol. Brain Res. 106: 124–135
Rosmarin A. G., Resendes K. K., Yang Z., McMillan J. N., Fleming S. L. (2004) GA-binding protein transcription factor: a review of GABP as an integrator of intracellular signaling and protein–protein interactions. Blood Cells Mol. Dis. 32: 143–154
Rothermel B. A., Vega R. B., Williams R. S. (2003) The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc. Med. 13: 15–21
Saitoh H., Hinchey J.(2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275: 6252–6258
Salinas S., Briancon-Marjollet A., Bossis G., Lopez M. A., Piechaczyk M., Jariel-Encontre I., Debant A., Hipskind R. A. (2004) SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J. Cell Biol. 165: 767–773
Sananbenesi F., Fischer A., Schrick C., Spiess J., Radulovic J. (2002) Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1. Mol. Cell Neurosci. 21: 463–476
Seeler J. S., Dejean A. (2003) Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4: 690–699
Sementchenko V. I., Watson D. K. (2000) Ets target genes: past, present and future. Oncogene 19: 6533–6548
Sgambato V., Vanhoutte P., Pages C., Rogard M., Hipskind R., Besson M. J., Caboche J. (1998) In vivo expression and regulation of Elk-1, a target of the extracellular-regulated kinase signaling pathway, in the adult rat brain. J. Neurosci. 18: 214–226
Shieh P. B., Hu S. C., Bobb K., Timmusk T., Ghosh A. (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 20: 727–740
Sitz J. H., Tigges M., Baumgartel K., Khaspekov L. G., Lutz B. (2004) Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4. Mol. Cell Biol. 24: 5821–5834
Slemmon J. R., Morgan J. I., Fullerton S. M., Danho W., Hilbush B. S., Wengenack T. M. (1996) Camstatins are peptide antagonists of calmodulin based upona conserved structural motif in PEP-19, neurogranin and neuromodulin. J. Biol. Chem. 271: 15911–15917
Slepnev V. I., De Camilli P. (2000) Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nat. Rev. Neurosci. 1: 161–172
Smith D. J., Stevens M. E., Sudanagunta S. P., Bronson R. T., Makhinson M., Watabe A. M., O’Dell T. J., Fung J., Weier H. U., Cheng J. F., Rubin E. M. (1997) Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 16: 28–36
Stasko M. R., Costa A. C. (2004) Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav Brain. Res. 154: 1–17
Su H. L., Li S. S. (2002) Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296: 65–73
Subramanian L., Benson M. D., Iniguez-Lluhi J. A. (2003) A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J. Biol. Chem. 278: 9134–9141
Swatton J. E., Sellers L. A., Faull R. L., Holland A., Iritani S., Bahn S. (2004) Increased MAP kinase activity in Alzheimer’s and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 19: 2711–2719
Sweatt J. D. (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 76: 1–10
Sweatt J. D., Weeber E. J. (2003) Genetics of childhood disorders: LII. Learning and memory, part 5: human cognitive disorders and the ras/ERK/CREB pathway. J. Am. Acad. Child Adolesc. Psychiatry 42: 873–876
Tao X., Finkbeiner S., Arnold D. B., Shaywitz A. J., Greenberg M. E. (1998) 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 20: 709–726
Teyssier C., Belguise K., Galtier F., Cavailles V., Chalbos D. (2003) Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. Mol. Endocrinol. 17: 287–299
Thomas G. M., Huganir R. L. (2004) MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 5: 173–183
Vanhoutte P., Nissen J. L., Brugg B., Gaspera B. D., Besson M. J., Hipskind R. A., Caboche J. (2001) Opposing roles of Elk-1 and its brain-specific isoform, short Elk-1, in nerve growth factor-induced PC12 differentiation. J. Biol. Chem. 276: 5189–5196
Vickers E. R., Kasza A., Kurnaz I. A., Seifert A., Zeef L. A., O’donnell A., Hayes A., Sharrocks A. D. (2004) Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol Cell Biol. 24: 10340–10351
Wang, J. C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C., and Yamamoto, K. R. (2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. USA. 101:15603–15608
Wang G. L., Timchenko N. A. (2005) Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein. Mol. Cell Biol. 25: 1325–1338
Watanabe H., Sawada J., Yano K., Yamaguchi K., Goto M., Handa H. (1993) cDNA cloning of transcription factor E4TF1 subunits with Ets and notch motifs. Mol. Cell Biol. 13: 1385–1391
West A. E., Chen W. G., Dalva M. B., Dolmetsch R. E., Kornhauser J. M., Shaywitz A. J., Takasu M. A., Tao X., Greenberg M. E. (2001) Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. USA. 98: 11024–11031
Wise P. M. (2002) Estrogens and neuroprotection. Trends Endocrinol. Metab. 13: 229–230
Woods Y. L., Rena G., Morrice N., Barthel A., Becker W., Guo S., Unterman T. G., Cohen P. (2001) The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem. J. 355: 597–607
Yang E. J., Ahn Y. S., Chung K. C. (2001) Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 276: 39819–39824
Yang S. H., Jaffray E., Hay R. T., Sharrocks A. D. (2003) Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol. Cell 12: 63–74
Acknowledgments
Due to space limitations, not all original work could be referenced. Apologies are extended to those whose work was not included. This work was supported by a grant from the Foundation Jerome Lejeune and from the National Institutes of Health, HD047671.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gardiner, K. Transcriptional Dysregulation in Down Syndrome: Predictions for Altered Protein Complex Stoichiometries and Post-translational Modifications, and Consequences for Learning/Behavior Genes ELK, CREB, and the Estrogen and Glucocorticoid Receptors. Behav Genet 36, 439–453 (2006). https://doi.org/10.1007/s10519-006-9051-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10519-006-9051-1